

Supporting Information for

Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Anti-atherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in *Ldlr*^{-/-} Mice

*Mikyung Yu**, *Jaume Amengual**, *Arjun Menon*, *Nazila Kamaly*, *Felix Zhou*, *Xiaoding Xu*, *Phei Er Saw*, *Seung-Joo Lee*, *Kevin Si*, *Carleena Angelica Ortega*, *Won Il Choi*, *In-Hyun Lee*, *Yazan Bdour*, *Jinjun Shi*, *Morteza Mahmoudi*, *Sangyong Jon*, *Edward A. Fisher[†]*, *Omid. C. Farokhzad[†]*




Figure S1. *In vitro* stabilities of the (A) NPs(550), (B) NPs(1000), and (C) NPs(2000) over 7 days. NPs(550), NPs(1000), and NPs(2000) were prepared with DSPE-mPEGs: DLPC (3:7 and 7:3), and incubated with PBS (green) and 10% FBS (pink), respectively, under gentle stirring (100 rpm) at 37°C. All the NPs with the molar ratio of DSPE-mPEGs: DLPC (7:3) were stable for 7 days in both PBS and 10% FBS.




Figure S2. Synthesis and characterization of Col IV-DSPE-PEG2000 conjugate. **(A)** Schematic of Col IV-DSPE-PEG2000 synthesis. The maleimide-functionalized DSPE-PEG2000 (DSPE-PEG2000-MAL) dissolved in chloroform was added to the Col IV-targeting peptide (KLWVLPKGGGC) that was previously dissolved in dry DMF. The reaction was stirred at RT for 24h, then the final product of Col IV-DSPE-PEG2000 conjugate was purified using HPLC. **(B)** MALDI TOF Mass Spectrometry measurement of DSPE-PEG2000-MAL and Col IV-DSPE-PEG2000 conjugate.




Figure S3. SPR sensorgrams obtained from BIAcore chips with immobilized collagen IV upon treatments with various concentrations of **(A)** Col IV-NPs(1000), **(B)** Col IV-NPs(2000), **(C)** NPs(1000), and **(D)** NPs(2000) (serial half dilution of the NPs from purple to black: purple: 5 mg/mL; yellow: 2.5 mg/mL; green: 1.25 mg/mL; red: 0.625 mg/mL; and black: 0.3 mg/mL). The RU value in Col IV-NPs(1000) was higher than those of other NPs.




Figure S4. *In vitro* stabilities of NP(1000) and Col IV-NP(1000) in serum (100% FBS) at 37°C. Data are expressed as mean \pm SEM.





Figure S5. The mean hydrodynamic size measurements of empty NPs, GW-NPs, and Col IV-GW-NPs determined by nanoparticle tracking analysis (NTA). Inset data are expressed as the mean \pm SEM.

(A)



(B)




Figure S6. Representative TEM images of the (A) empty NPs stained with 0.75% uranyl formate and (B) GW-NPs stained with 1% uranyl acetate. Scale bars represent 100 nm.




Figure S7. Synthetic scheme for GW-BODIPY conjugate.




Figure S8. IVIS images for the relative accumulations of GW-BODIPY and PLA-Cy5.5 in the aorta and liver.